Enzymatica Reports Strong Q1 2025 Performance Amid Focus on International Growth
In its latest quarterly report for the first quarter of 2025, Swedish biotech company Enzymatica has shown promising progress as it aims to solidify its foothold in domestic markets while eyeing international expansion. The report, released on April 29, reveals that the company's net sales reached SEK 12.3 million, a notable increase from SEK 9.4 million compared to the same period in the previous year. However, the company still reported an operating loss of SEK 18.0 million, slightly improving from the SEK 18.4 million loss reported last year.
Key Financial Figures:
CEO Claus Egstrand commented on the results, emphasizing the significant growth of the ColdZyme product in the pharmacy sector. ColdZyme has not only gained a stronger market presence, but it has also outperformed the broader market, reflecting a remarkable increase in sales of 31.5% in Sweden and 19.5% in the UK year-over-year. These results indicate that ColdZyme is resonating well with consumers, garnering appreciation for its effectiveness.
Despite these positive domestic results, Egstrand pointed out that Enzymatica's vision extends beyond its home markets. The company views its patented technology as a gateway to substantial sales growth through new partnerships and international markets. This strategy aligns with the company's focus on global expansion.
Research Validation of ColdZyme:
Recently, on February 28, 2025, two independent studies regarding ColdZyme were published in the prestigious Journal of Physiology. Conducted by distinguished institutions including the University of Kent and a university in Vienna, these studies demonstrated significant health benefits associated with the use of ColdZyme. The first clinical study involving 154 participants found that ColdZyme effectively reduced viral load by 94% and alleviated cold symptoms, leading to fewer sick days and milder symptoms. The in vitro study confirmed its effectiveness in preventing viral infections in upper respiratory tract cells, providing further evidence to validate ColdZyme's therapeutic claims.
On March 5, Enzymatica hosted a press conference to discuss these findings, featuring presentations from esteemed researchers, including Professor Glen Davison and Professor Doris Wilflingseder. The conference reinforced the company’s commitment to transparency and the dissemination of scientific research.
Going forward, Enzymatica appears poised for growth as it ventures into new markets and builds on the solid foundation established in domestic sales. As they continue to innovate and expand access to ColdZyme, both consumers and shareholders are likely to benefit from the strategic direction outlined in the latest report.
Enzymatica AB, founded in Lund, is publicly listed on the Nasdaq First North Growth Market, and is known for its commitment to providing innovative health solutions using scientific research and technology. Stakeholders looking for more details or updates can explore further on their website: www.enzymatica.se.
Key Financial Figures:
- - Net Sales: SEK 12.3 million (up from SEK 9.4 million)
- - Operating Result: SEK -18.0 million (versus SEK -18.4 million)
- - Earnings per Share: SEK -0.07 (compared to SEK -0.11)
- - Cash Flow from Operating Activities: SEK -8.5 million (previously SEK -7.3 million)
CEO Claus Egstrand commented on the results, emphasizing the significant growth of the ColdZyme product in the pharmacy sector. ColdZyme has not only gained a stronger market presence, but it has also outperformed the broader market, reflecting a remarkable increase in sales of 31.5% in Sweden and 19.5% in the UK year-over-year. These results indicate that ColdZyme is resonating well with consumers, garnering appreciation for its effectiveness.
Despite these positive domestic results, Egstrand pointed out that Enzymatica's vision extends beyond its home markets. The company views its patented technology as a gateway to substantial sales growth through new partnerships and international markets. This strategy aligns with the company's focus on global expansion.
Research Validation of ColdZyme:
Recently, on February 28, 2025, two independent studies regarding ColdZyme were published in the prestigious Journal of Physiology. Conducted by distinguished institutions including the University of Kent and a university in Vienna, these studies demonstrated significant health benefits associated with the use of ColdZyme. The first clinical study involving 154 participants found that ColdZyme effectively reduced viral load by 94% and alleviated cold symptoms, leading to fewer sick days and milder symptoms. The in vitro study confirmed its effectiveness in preventing viral infections in upper respiratory tract cells, providing further evidence to validate ColdZyme's therapeutic claims.
On March 5, Enzymatica hosted a press conference to discuss these findings, featuring presentations from esteemed researchers, including Professor Glen Davison and Professor Doris Wilflingseder. The conference reinforced the company’s commitment to transparency and the dissemination of scientific research.
Going forward, Enzymatica appears poised for growth as it ventures into new markets and builds on the solid foundation established in domestic sales. As they continue to innovate and expand access to ColdZyme, both consumers and shareholders are likely to benefit from the strategic direction outlined in the latest report.
Enzymatica AB, founded in Lund, is publicly listed on the Nasdaq First North Growth Market, and is known for its commitment to providing innovative health solutions using scientific research and technology. Stakeholders looking for more details or updates can explore further on their website: www.enzymatica.se.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.